Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sipagladenant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A known ✓ | P29274 | 6/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17912334 | 0.95 | L3MBTL1 (0.46) | L3MBTL1KDM4EALDH1A1POLBPKM | |
| SCHEMBL20057578 | 0.92 | L3MBTL1 (0.52) | L3MBTL1KDM4EALDH1A1POLBPKM | |
| SCHEMBL1255746 | 0.91 | L3MBTL1 (0.47) | L3MBTL1KDM4EALDH1A1POLBPKM | |
| SCHEMBL879437 | 0.91 | L3MBTL1 (0.46) | L3MBTL1KDM4EALDH1A1POLBPKM | |
| SCHEMBL10331934 | 0.90 | L3MBTL1 (0.46) | L3MBTL1KDM4EALDH1A1POLBPKM | |
| SCHEMBL846371 | 0.90 | L3MBTL1 (0.44) | L3MBTL1KDM4EALDH1A1POLBPKM | |
| SCHEMBL1257097 | 0.89 | L3MBTL1 (0.46) | L3MBTL1KDM4EALDH1A1POLBPKM | |
| SCHEMBL1255617 | 0.89 | L3MBTL1 (0.51) | L3MBTL1KDM4EALDH1A1POLBPKM | |
| SCHEMBL846136 | 0.89 | TDP1 (0.44) | L3MBTL1KDM4EALDH1A1POLBPKM | |
| SCHEMBL1256996 | 0.88 | L3MBTL1 (0.52) | L3MBTL1KDM4EALDH1A1POLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393606-A1 | THERAPEUTIC AGENT FOR FRONTAL LOBE DYSFUNCTION | KYOWA HAKKO KIRIN CO LTD (JP) | 2021-12-23 | — | — | US | disclosed |
| EP-3270923-B1 | THERAPEUTIC AGENT FOR FRONTAL LOBE DYSFUNCTION | KYOWA KIRIN CO LTD (JP) | 2021-05-26 | — | — | EP | disclosed |
| EP-3822269-A1 | PRODUCTION METHOD OF THIAZOLE DERIVATIVE | Kyowa Kirin Co., Ltd. (JP) | 2021-05-19 | — | — | EP | disclosed |
| US-10894790-B2 | Production method of thiazole derivative | KYOWA KIRIN CO., LTD (JP) | 2021-01-19 | — | — | US | disclosed |
| EP-3242877-B1 | PRODUCTION METHOD OF THIAZOLE DERIVATIVE | KYOWA KIRIN CO LTD (JP) | 2020-12-16 | — | — | EP | disclosed |
| US-20200247798-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA KIRIN CO LTD (JP) | 2020-08-06 | — | — | US | disclosed |
| US-20200216438-A1 | PRODUCTION METHOD OF THIAZOLE DERIVATIVE | KYOWA KIRIN CO LTD (JP) | 2020-07-09 | — | — | US | disclosed |
| US-10407440-B2 | Therapeutic agent for motor disorders | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190144438-A1 | PRODUCTION METHOD OF THIAZOLE DERIVATIVE | KYOWA KIRIN CO., LTD. (JP) | 2019-05-16 | — | — | US | disclosed |
| US-20180125835-A1 | Dosage and Use of an A2A Antagonist | H. LUNDBECK A/S (DK) | 2018-05-10 | — | — | US | disclosed |
| US-7880013-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| WO-2010126082-A1 | THERAPEUTIC AGENT FOR MOTOR DISORDERS | 協和発酵キリン株式会社 (JP) | 2010-11-04 | — | — | WO | disclosed |
| US-20100256361-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100152162-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-7718808-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-7718808-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-7718808-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| EP-1921077-A1 | AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1700856-A1 | THIAZOLE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393606-A1 | THERAPEUTIC AGENT FOR FRONTAL LOBE DYSFUNCTION | LRRK2, PYGB, SNCA | ADORA2A 1116/4885L3MBTL1 2600/4885KDM4E 3123/4885 |
| US-10407440-B2 | Therapeutic agent for motor disorders | DDT, COMT, SLC6A3 | ADORA2A 497/4885L3MBTL1 699/4885KDM4E 4721/4885 |
| US-20180125835-A1 | Dosage and Use of an A2A Antagonist | ADORA2A, HTR5A, ADORA2B | ADORA2A 1/4885L3MBTL1 3434/4885KDM4E 3777/4885 |
| US-20190144438-A1 | PRODUCTION METHOD OF THIAZOLE DERIVATIVE | ADORA2A, HTR1A, ADORA2B | ADORA2A 1/4885L3MBTL1 1740/4885KDM4E 3630/4885 |
| US-20100256361-A1 | THIAZOLE DERIVATIVES | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885L3MBTL1 2618/4885KDM4E 4728/4885 |
| US-20200216438-A1 | PRODUCTION METHOD OF THIAZOLE DERIVATIVE | ADORA2A, HTR1A, ADORA2B | ADORA2A 1/4885L3MBTL1 1740/4885KDM4E 3630/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885L3MBTL1 2473/4885KDM4E 4715/4885 |
| US-10894790-B2 | Production method of thiazole derivative | ADORA2A, HTR1A, ADORA2B | ADORA2A 1/4885L3MBTL1 1740/4885KDM4E 3630/4885 |
| US-20200247798-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | TAAR1, SLC6A1, GABBR1 | ADORA2A 82/4885L3MBTL1 1461/4885KDM4E 3799/4885 |
| US-20100152162-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER | HCRTR1, MTNR1A, HCRTR2 | ADORA2A 525/4885L3MBTL1 1732/4885KDM4E 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.